Table. Hazard Ratios for Death in PD-L1–High NSCLC by KRAS Status and Treatment Regimen.
| Values | HR (95% CI) | |
|---|---|---|
| Unadjusted | Adjusteda | |
| Prognostic value of KRAS status | ||
| ICI monotherapy | ||
| KRAS variant | 0.79 (0.64-0.98) | 0.77 (0.61-0.98) |
| KRAS wild type | 1 [Reference] | 1 [Reference] |
| Chemoimmunotherapy | ||
| KRAS variant | 0.98 (0.73-1.33) | 0.99 (0.70-1.40) |
| KRAS wild type | 1 [Reference] | 1 [Reference] |
| Predictive value of KRAS status | ||
| KRAS variant | ||
| ICI monotherapy | 1.04 (0.80-1.35) | 1.03 (0.75-1.40) |
| Chemoimmunotherapy | 1 [Reference] | 1 [Reference] |
| KRAS wild type | ||
| ICI monotherapy | 1.27 (0.99-1.64) | 1.19 (0.89-1.58) |
| Chemoimmunotherapy | 1 [Reference] | 1 [Reference] |
Abbreviations: ECOG, Eastern Cooperative Oncology Group; HR, hazard ratio; ICI, immune checkpoint inhibition; NSCLC, non–small-cell lung cancer; PD-L1, programmed cell death ligand 1.
a
Multivariable Cox model adjusted for age, sex, race/ethnicity, ECOG performance status, disease stage, and smoking history. Missing values for ECOG performance status were imputed by multiple chained imputation.